Literature DB >> 15726589

Survival outcome of patients with nasopharyngeal carcinoma with first local failure: a study by the Hong Kong Nasopharyngeal Carcinoma Study Group.

Kwok Hung Yu1, Sing Fai Leung, Stewart Yuk Tung, Benny Zee, Daniel T T Chua, Wai Man Sze, Stephen C K Law, Michael K M Kam, To Wai Leung, Jonathan S T Sham, Anne W M Lee, Joseph S K Au, Edwin P Hui, Wing Kin Sze, Ashley C K Cheng, T K Yau, Roger K C Ngan, Frank C S Wong, Gordon K H Au, Anthony T C Chan.   

Abstract

BACKGROUND: The purpose of this article is to report the overall survival (OS) outcome of patients with nasopharyngeal carcinoma (NPC) with local failure who received salvage treatment and to identify prognostic factors for OS.
METHODS: Between January 1996 and December 2000, 2915 patients received primary radiotherapy (RT) with or without chemotherapy for nonmetastatic NPC. At a median follow-up of 3.1 years, 319 patients had developed local failure as the first failure, with or without synchronous regional/distant failure. OS was calculated from the start of primary RT. Univariate and multivariate analyses were performed to identify prognostic factors for OS in patients with isolated local failure.
RESULTS: The T classification distribution of the local failure (rT classification) was as follows: 68 (21%) rT1 to T2a, 92 (29%) rT2b, 82 (26%) rT3, and 77 (24%) rT4. The rT classification was the same as the initial T classification in 82% of patients. Two hundred seventy-five patients (86%) had isolated local failure, and 232 (84%) of them did not have any distant metastasis or regional failure develop during follow-up. Salvage treatment was given to 200 patients (73%) with isolated local failure. One hundred fifty-nine patients (80%) received reirradiation (108 external beam RT [EBRT], 44 brachytherapy, and seven EBRT plus brachytherapy), 22 patients (11%) underwent nasopharyngectomy with or without postoperative RT, and 19 patients (9%) were treated with chemotherapy alone. Four patients died of RT complications, and one died of chemotherapy toxicity in the absence of active NPC. The 3-year actuarial OS for patients with isolated local failure was 74%. On multivariate analysis, advanced initial T classification (hazard ratio [HR], 1.44; p = .0006) and the use of salvage treatment (HR, 0.54; p = .0038) were independent prognostic factors. For the subgroups of patients who had the same recurrent and initial T classification, salvage treatment was associated with improved OS only in the subgroup with T1 to T2 local failure (n = 127; p = 0.0446), but not in the subgroups with T3 (n = 48) or T4 (n = 54) disease.
CONCLUSIONS: Most patients with first local failure have localized disease. Salvage treatment is feasible in most of the patients with clinically isolated local failure. Patients who had early initial T classification have a more favorable prognosis. Subgroup analysis suggests that salvage treatment only prolongs survival in patients with T1 to T2 recurrent disease. 2005 Wiley Periodicals, Inc.

Entities:  

Mesh:

Year:  2005        PMID: 15726589     DOI: 10.1002/hed.20161

Source DB:  PubMed          Journal:  Head Neck        ISSN: 1043-3074            Impact factor:   3.147


  43 in total

Review 1.  Recurrent nasopharyngeal carcinoma: a clinical dilemma and challenge.

Authors:  Tao Xu; J Tang; M Gu; L Liu; W Wei; H Yang
Journal:  Curr Oncol       Date:  2013-10       Impact factor: 3.677

Review 2.  Does East meet West? Towards a unified vision of the management of Nasopharyngeal carcinoma.

Authors:  Elaine Johanna Limkin; Pierre Blanchard
Journal:  Br J Radiol       Date:  2019-05-31       Impact factor: 3.039

3.  Surgical salvage of recurrent nasopharyngeal carcinoma.

Authors:  Jimmy Yu Wai Chan
Journal:  Curr Oncol Rep       Date:  2015-03       Impact factor: 5.075

4.  Diffusion-Weighted Imaging of Nasopharyngeal Carcinoma: Can Pretreatment DWI Predict Local Failure Based on Long-Term Outcome?

Authors:  B K H Law; A D King; K S Bhatia; A T Ahuja; M K M Kam; B B Ma; Q Y Ai; F K F Mo; J Yuan; D K W Yeung
Journal:  AJNR Am J Neuroradiol       Date:  2016-05-05       Impact factor: 3.825

5.  Salvage endoscopic nasopharyngectomy for local recurrent or residual nasopharyngeal carcinoma: a 10-year experience.

Authors:  Juan Liu; Huapeng Yu; Xicai Sun; Dehui Wang; Yurong Gu; Quan Liu; Huan Wang; Wade Han; Allison Fry
Journal:  Int J Clin Oncol       Date:  2017-06-10       Impact factor: 3.402

6.  A preliminary report on the role of endoscopic endonasal nasopharyngectomy in recurrent rT3 and rT4 nasopharyngeal carcinoma.

Authors:  Eugene Hung Chih Wong; Yew Toong Liew; Mohd Zulkiflee Abu Bakar; Elizabeth Yenn Lynn Lim; Narayanan Prepageran
Journal:  Eur Arch Otorhinolaryngol       Date:  2016-08-12       Impact factor: 2.503

7.  Stereotactic radiosurgery may contribute to overall survival for patients with recurrent head and neck carcinoma.

Authors:  Koji Kawaguchi; Kengo Sato; Akihisa Horie; Susumu Iketani; Hiroyuki Yamada; Yasunori Nakatani; Junichi Sato; Yoshiki Hamada
Journal:  Radiat Oncol       Date:  2010-06-09       Impact factor: 3.481

Review 8.  Current treatment options for recurrent nasopharyngeal cancer.

Authors:  Carlos Suárez; Juan P Rodrigo; Alessandra Rinaldo; Johannes A Langendijk; Ashok R Shaha; Alfio Ferlito
Journal:  Eur Arch Otorhinolaryngol       Date:  2010-09-24       Impact factor: 2.503

9.  A nomogram to predict loco-regional control after re-irradiation for head and neck cancer.

Authors:  Nadeem Riaz; Julian C Hong; Eric J Sherman; Luc Morris; Matthew Fury; Ian Ganly; Tony J C Wang; Weji Shi; Suzanne L Wolden; Andrew Jackson; Richard J Wong; Zhigang Zhang; Shyam D Rao; Nancy Y Lee
Journal:  Radiother Oncol       Date:  2014-06-30       Impact factor: 6.280

10.  Outcome of surgical management of persistent or recurrent neck mass in patients with nasopharyngeal carcinoma after radiotherapy.

Authors:  Cheng-Yu Lin; Sen-Tien Tsai; Ying-Tai Jin; Ming-Wei Yang; I-Chun Yeh; Jenn-Ren Hsiao
Journal:  Eur Arch Otorhinolaryngol       Date:  2007-12-07       Impact factor: 2.503

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.